CYTX Cytori Therapeutics

Cytori to Webcast Third Quarter Financial Results on November 9

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Wednesday, November 9, 2016 at 5:30 PM Eastern Time.

The dial-in information is as follows:

Dial-In Number: +1.877.402.3914

Conference ID: 9218454

Prior to the webcast at approximately 4:15 PM Eastern Time on November 9, Cytori will issue its third quarter earnings release which will review Cytori’s third quarter performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.

About Cytori Therapeutics, Inc.

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com or follow Cytori.

EN
26/10/2016

Underlying

CYTXCytori Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cytori Therapeutics

 PRESS RELEASE
Free
CYTX Cytori Therapeu...

Cytori Strengthens Global Intellectual Property Portfolio with Key Pat...

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) (“Cytori” or the “Company”) announced today the issuance of a number of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has over 90 global patents issued and another 55 patent applications pending around the globe. Several of Cytori’s recently-issued patents contain claims providing protections for Cytori’s program in the use of Cytori Cell Therapy™ for treating scleroderma. Cytori recently completed enrollme...

November 16, 2016 1 EN
 PRESS RELEASE
Free
CYTX Cytori Therapeu...

Cytori Granted FDA Orphan Drug Designation for ECCS-50 in Scleroderma

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted Cytori an orphan drug designation for cryopreserved or centrally processed ECCS-50 for scleroderma. “This orphan drug designation is part of our long-term strategy to facilitate the autologous retreatment of patients with scleroderma, if it is needed,” said Dr. Marc Hedrick, President and CEO of Cytori Therapeutics. “Our development plan for cryopreserved ECCS-50...

November 14, 2016 1 EN
 PRESS RELEASE
Free
CYTX Cytori Therapeu...

Cytori Reports Third Quarter 2016 Business and Financial Results

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced its third quarter financial results and provided updates on its corporate activity and clinical development. Third quarter 2016 net loss allocable to common stockholders was $5.4 million and $0.26 per share. Operating cash burn was approximately $4.6 million in the third quarter 2016. Cytori ended the third quarter of 2016 with approximately $15 million of cash and cash equivalents. Selected Recent Highl...

November 9, 2016 1 EN
 PRESS RELEASE
Free
CYTX Cytori Therapeu...

Cytori to Present Data in Two Distinct Models of Impaired Wound Healin...

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present new preclinical data describing positive effects of Cytori Cell Therapy™ on a corneal wound healing model and in cutaneous scarring following burn injury. The data will be presented at the International Federation for Adipose Therapeutics (IFATS) in San Diego on November 17-20, 2016. One presentation is titled “Adipose-Derived Regenerative Cells Promote Proliferation of Corneal Epithelial Cell And Corneal Wound Healing.” This presentatio...

November 4, 2016 1 EN
 PRESS RELEASE
Free
CYTX Cytori Therapeu...

Cytori to Webcast Third Quarter Financial Results on November 9

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Wednesday, November 9, 2016 at 5:30 PM Eastern Time. The dial-in information is as follows: Dial-In Number: +1.877.402.3914Conference ID: 9218454 Prior to the webcast at approximately 4:15 PM Eastern Time on November 9, Cytori will issue its third quarter earnings release which will review Cytori’s third quarter performance. The webcast will be availa...

October 26, 2016 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch